J
James M. Cleary
Researcher at Harvard University
Publications - 195
Citations - 10062
James M. Cleary is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 37, co-authored 158 publications receiving 6018 citations. Previous affiliations of James M. Cleary include Brigham and Women's Hospital & Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Vasanthi S. Viswanathan,Matthew J. Ryan,Harshil Dhruv,Shubhroz Gill,Ossia M. Eichhoff,Brinton Seashore-Ludlow,Samuel D. Kaffenberger,John K. Eaton,Kenichi Shimada,Andrew J. Aguirre,Andrew J. Aguirre,Srinivas R. Viswanathan,Srinivas R. Viswanathan,Shrikanta Chattopadhyay,Pablo Tamayo,Pablo Tamayo,Wan Seok Yang,Matthew G. Rees,Sixun Chen,Zarko V. Boskovic,Sarah Javaid,Cherrie Huang,Xiaoyun Wu,Yuen-Yi Tseng,Elisabeth Roider,Dong Gao,James M. Cleary,Brian M. Wolpin,Jill P. Mesirov,Jill P. Mesirov,Daniel A. Haber,Daniel A. Haber,Jeffrey A. Engelman,Jesse S. Boehm,Joanne Kotz,Cindy S. Hon,Yu Chen,William C. Hahn,William C. Hahn,Mitchell P. Levesque,John G. Doench,Michael E. Berens,Alykhan F. Shamji,Paul A. Clemons,Brent R. Stockwell,Stuart L. Schreiber,Stuart L. Schreiber,Stuart L. Schreiber +47 more
TL;DR: Vulnerability to ferroptic cell death induced by inhibition of a lipid peroxidase pathway as a feature of therapy-resistant cancer cells across diverse mesenchymal cell-state contexts is identified.
Journal ArticleDOI
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer,Eric Van Cutsem,Alfredo Falcone,Takayuki Yoshino,Rocio Garcia-Carbonero,Nobuyuki Mizunuma,Kentaro Yamazaki,Yasuhiro Shimada,Josep Tabernero,Yoshito Komatsu,Alberto Sobrero,Eveline Boucher,Marc Peeters,Ben Tran,Heinz-Josef Lenz,Alberto Zaniboni,Howard S. Hochster,James M. Cleary,Hans Prenen,Fabio Benedetti,Hirokazu Mizuguchi,Lukas Makris,Masanobu Ito,Atsushi Ohtsu +23 more
TL;DR: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival, and this phase 3 trial was the first to report this result.
Journal ArticleDOI
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y. Janjigian,Yelena Y. Janjigian,Kohei Shitara,Markus Moehler,Marcelo Garrido,Pamela Salman,Lin Shen,Lucjan Wyrwicz,Kensei Yamaguchi,Tomasz Skoczylas,Arinilda Silva Campos Bragagnoli,Tianshu Liu,Michael Schenker,Patricio Eduardo Yanez,Mustapha Tehfe,Ruben Dario Kowalyszyn,Michalis V. Karamouzis,Ricardo Bruges,Thomas Zander,Roberto Pazo-Cid,Erika Hitre,Kynan Feeney,James M. Cleary,Valerie Poulart,Dana Cullen,Ming Lei,H. Xiao,Kaoru Kondo,M. Li,Jaffer A. Ajani +29 more
TL;DR: The CheckMate 649 trial as discussed by the authors evaluated first-line programmed cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction, and oesophage alogaryal adenocarcinoma.
Journal ArticleDOI
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Ronan J. Kelly,Jaffer A. Ajani,Jarosław Kużdżał,Thomas Zander,Eric Van Cutsem,Guillaume Piessen,Guillermo Mendez,Josephine Feliciano,Satoru Motoyama,Astrid Lièvre,Hope E. Uronis,Elena Elimova,Cecile Grootscholten,Karen Geboes,Syed Nabeel Zafar,Stephanie J Snow,Andrew H. Ko,Kynan Feeney,Michael Schenker,Piotr Kocoń,Jenny Zhang,Lili Zhu,Ming Lei,Prianka Singh,Kaoru Kondo,James M. Cleary,Markus Moehler +26 more
TL;DR: In this paper, no adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageaal...
Journal ArticleDOI
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa,Teresa Macarulla,Milind Javle,Robin Kate Kelley,Sam J. Lubner,Jorge Adeva,James M. Cleary,Daniel V.T. Catenacci,Mitesh J. Borad,John Bridgewater,William P. Harris,Adrian Murphy,Do Youn Oh,Jonathan R. Whisenant,Maeve A. Lowery,Lipika Goyal,Rachna T. Shroff,Anthony B. El-Khoueiry,Bin Fan,Bin Wu,Christina X. Chamberlain,Liewen Jiang,Camelia Gliser,Shuchi Sumant Pandya,Juan W. Valle,Andrew X. Zhu,Andrew X. Zhu +27 more
TL;DR: Progression-free survival was significantly improved with ivosidenib compared with placebo, and ivOSidenib was well tolerated, and this study shows the clinical benefit of targeting IDH1 mutations in advanced,IDH1-mutant cholangiocarcinoma.